UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CELL & GENE THERAPY

Sartorius

S

Sartorius

Cell & Gene TherapyGöttingen, Germany
Visit Website

About Sartorius

Sartorius is one of the few life science companies to have grown continuously for over 150 years, tracing its origins to Göttingen, Germany, in 1870. Today it serves as a critical partner to biopharma manufacturers and research laboratories worldwide, supplying the equipment, consumables, and data analytics tools that underpin the development and production of biological medicines.

Bioprocess Solutions: The Industrial Core

The company's Bioprocess Solutions division is its largest business segment, focused on upstream and downstream bioprocessing. Sartorius supplies single-use bioreactors, filtration systems, cell culture media, and chromatography equipment used in the manufacture of monoclonal antibodies, vaccines, cell and gene therapies, and other biologics. Its Stedim brand, brought into the group through the acquisition of Sartorius Stedim Biotech, is widely recognised across manufacturing floors globally. The division's single-use technology portfolio has become a standard reference point for contract development and manufacturing organisations and integrated biopharma producers alike.

Lab Products & Services: Precision at the Bench

The Lab Products & Services division serves research and quality-control laboratories with high-precision balances, pipettes, laboratory water purification systems, and related instruments. These products carry the company's longstanding reputation for measurement accuracy, rooted in its original weighing instrument heritage. Software platforms including the Sartorius Data Intelligence suite extend the offering into digital process analytics and lab data management.

Sartorius is listed on the Frankfurt Stock Exchange and is a constituent of several major European indices, reflecting its scale as a multi-billion-euro revenue business with a presence across more than 110 countries. Manufacturing and R&D sites span Europe, North America, and Asia-Pacific, with a significant operational footprint in France through its Sartorius Stedim Biotech subsidiary, which is separately listed on Euronext Paris.

The company has grown substantially through acquisition as well as organic expansion, incorporating data analytics specialists such as Umetrics and BIA Separations to strengthen its digital and process chromatography capabilities. Its customer base spans early-stage biotechs through to the world's largest pharmaceutical manufacturers.

Further information is available at sartorius.com.

Similar Companies

More in Cell & Gene Therapy

B

Bayer

Bayer is one of the oldest and most globally recognised life sciences companies in the world, founded in Barmen, Germany in 1863 and responsible for introducing aspirin to modern medicine. Today the company operates across more than 100 countries, employing tens of thousands of people and generating revenues in the tens of billions of euros annually, with its shares listed on the Frankfurt Stock Exchange under the ticker BAYN. Pharmaceuticals Division Bayer's pharmaceuticals business focuses on four core therapeutic areas: cardiovascular disease, oncology, gynaecology, and ophthalmology. The company's cardiovascular portfolio is among the most recognised in the industry, anchored by Xarelto (rivaroxaban), one of the world's most widely prescribed oral anticoagulants. In oncology, Bayer has built a substantial presence in targeted therapies, including treatments for renal cell carcinoma and thyroid cancer. The division also holds a strong position in women's health, with a broad contraception and fertility product range distributed globally. Crop Science & Consumer Health Beyond pharmaceuticals, Bayer operates one of the world's largest crop science divisions, a segment significantly expanded following the acquisition of Monsanto in 2018. This business covers herbicides, fungicides, insecticides, and seeds, making Bayer a central player in global agricultural supply chains. The company's consumer health division, which markets established brands in pain relief, dermatology, nutritional supplements, and allergy care, was partially divested through a strategic review, reflecting Bayer's continued focus on its prescription and crop science core. Bayer's research and development investment spans biologics, cell and gene therapy, and radiopharmaceuticals, with the company actively expanding its pipeline through both internal programmes and external partnerships and acquisitions. Its global headquarters remain in Leverkusen, Germany, where the company was formally established. Further information is available at bayer.com.

View profile
E

Endpoints News

The go-to daily news source for the global biopharma industry, Endpoints News covers clinical trials, drug approvals, regulatory decisions, and the business of drug development with a focus that competing outlets rarely match. Founded in 2016 by veteran journalist John Carroll, the publication built its reputation on breaking news and deeply reported stories aimed squarely at the professionals who run, fund, and work inside pharmaceutical and biotechnology companies. Endpoints reaches a subscriber base of researchers, executives, investors, and regulatory professionals who rely on its coverage to track pipeline developments, FDA and EMA actions, licensing deals, and IPO activity. Its morning newsletter, Endpoints Weekly, and real-time alerts have become standard reading across the industry, distinguishing Endpoints from broader business media through its specialist depth and speed. The outlet provides coverage across a wide range of therapy areas including oncology, rare disease, gene therapy, immunology, and neuroscience, following assets from early-stage research through approval and commercialisation. In 2022, Endpoints News was acquired by Citeline, a data and intelligence business serving the life sciences sector, which positioned the publication within a broader ecosystem of clinical and commercial intelligence tools. Based in Boston, Massachusetts, Endpoints operates as a specialist industry media brand with a global editorial remit, covering developments in the United States, Europe, and Asia. Its journalists attend major industry conferences and produce long-form investigative pieces alongside its rapid-fire news output. Further information is available at endpts.com.

View profile
C

CSL

CSL Limited is one of the world's largest biotechnology companies by market capitalisation, built on more than a century of plasma science and vaccine development. Founded in 1916 as the Commonwealth Serum Laboratories in Melbourne, Australia, the company has grown from a government research body into a global ASX- and ADR-listed biotherapeutics group operating across more than 100 countries. Plasma-Derived Therapies and Behring The company's flagship division, CSL Behring, is among the world's leading manufacturers of plasma-derived therapies, supplying immunoglobulins, albumin, coagulation factors, and specialty products to patients with rare and serious conditions including primary immune deficiencies, haemophilia, and hereditary angioedema. CSL Behring operates one of the largest plasma collection networks globally, with hundreds of donation centres across North America and Europe, underpinning a manufacturing supply chain that processes tens of millions of litres of plasma each year. Seqirus and Influenza Vaccine Leadership CSL's second major division, Seqirus, is one of the two largest influenza vaccine producers in the world. Operating high-containment manufacturing facilities in the United Kingdom, the United States, and Australia, Seqirus supplies seasonal and pandemic influenza vaccines to governments and healthcare systems globally, including longstanding contracts with national immunisation programmes. The division's cell-based and adjuvanted vaccine technologies are recognised by public health authorities as meaningful advances over traditional egg-based manufacturing. In 2022 CSL completed the acquisition of Vifor Pharma, a Swiss-headquartered specialist in iron deficiency, nephrology, and cardio-renal therapies, substantially expanding the group's product portfolio and its presence in hospital and renal care markets. CSL is headquartered in Melbourne, Australia, with major operational hubs in King of Prussia (Pennsylvania), Marburg (Germany), and Bern (Switzerland). The group invests heavily in research and development, with a pipeline spanning recombinant therapies, gene therapy, and next-generation plasma fractionation. CSL's scale, century-long heritage in biologics manufacturing, and vertically integrated plasma network position it as a critical supplier to healthcare systems managing rare, chronic, and infectious disease. Further information is available at csl.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy